Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains

Overview

Journal Vaccines (Basel)

Date 2025 Jan 8

PMID 39771973

Authors

Ana C B Terzian

Sasha R Azar

Cassia F Estofolete

Mauricio L Nogueira

Nikos Vasilakis

Affiliations

Soon will be listed here.

Abstract

: Yellow fever virus (YFV) (, ) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. : The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. : Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT 183, PRNT 86, median reciprocal PRNT 80, and PRNT 40) compared to 17D-204 (mean reciprocal PRNT 91, PRNT 33, median reciprocal PRNT 40, and PRNT 10). : Our data indicate antigenic differences between 17D and 17DD vaccines.

References

Vasilakis N, Shell E, Fokam E, Mason P, Hanley K, Estes D . Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology. 2006; 358(2):402-12. PMC: 3608925. DOI: 10.1016/j.virol.2006.08.049. View

Barrett A, Teuwen D . Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol. 2009; 21(3):308-13. DOI: 10.1016/j.coi.2009.05.018. View

Monath T . Yellow fever: an update. Lancet Infect Dis. 2002; 1(1):11-20. DOI: 10.1016/S1473-3099(01)00016-0. View

Gardner C, Ryman K . Yellow fever: a reemerging threat. Clin Lab Med. 2010; 30(1):237-60. PMC: 4349381. DOI: 10.1016/j.cll.2010.01.001. View

Akondy R, Monson N, Miller J, Edupuganti S, Teuwen D, Wu H . The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009; 183(12):7919-30. PMC: 3374958. DOI: 10.4049/jimmunol.0803903. View

Ishikawa T, Yamanaka A, Konishi E . A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014; 32(12):1326-37. DOI: 10.1016/j.vaccine.2014.01.040. View

Ma J, Boudewijns R, Sanchez-Felipe L, Mishra N, Vercruysse T, Kum D . Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Emerg Microbes Infect. 2021; 10(1):2279-2290. PMC: 8648041. DOI: 10.1080/22221751.2021.2008772. View

Beck A, Barrett A . Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015; 14(11):1479-92. PMC: 5563254. DOI: 10.1586/14760584.2015.1083430. View

Theiler M, Smith H . THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS. J Exp Med. 2009; 65(6):767-86. PMC: 2133530. DOI: 10.1084/jem.65.6.767. View

10.

Dutta S, Langenburg T . A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses. 2023; 15(4). PMC: 10142581. DOI: 10.3390/v15040860. View

11.

Saito Y, Moi M, Takeshita N, Lim C, Shiba H, Hosono K . Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect Dis. 2016; 16(1):578. PMC: 5070094. DOI: 10.1186/s12879-016-1873-8. View

12.

POLAND J, Calisher C, Monath T, DOWNS W, Murphy K . Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900. PMC: 2396120. View

13.

Ferreira C, Campi-Azevedo A, Peruhype-Magalhaes V, Costa-Pereira C, de Albuquerque C, Muniz L . The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev Vaccines. 2017; 17(1):79-90. DOI: 10.1080/14760584.2018.1406800. View

14.

Jennings A, Whitby J, Minor P, Barrett A . Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. Vaccine. 1993; 11(6):679-81. DOI: 10.1016/0264-410x(93)90317-q. View

15.

de Melo A, da Silva M, Magalhaes M, Gil L, Freese de Carvalho E, Braga-Neto U . Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. 2011; 85(4):739-47. PMC: 3183786. DOI: 10.4269/ajtmh.2011.10-0496. View

16.

Vasilakis N, Durbin A, Travassos da Rosa A, Munoz-Jordan J, Tesh R, Weaver S . Antigenic relationships between sylvatic and endemic dengue viruses. Am J Trop Med Hyg. 2008; 79(1):128-32. View

17.

. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations. Vaccine. 2014; 33(1):76-7. DOI: 10.1016/j.vaccine.2014.05.040. View

18.

James E, LaFond R, Gates T, Mai D, Malhotra U, Kwok W . Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013; 87(23):12794-804. PMC: 3838168. DOI: 10.1128/JVI.01160-13. View

19.

Fischer C, Oliveira-Filho E, Drexler J . Viral emergence and immune interplay in flavivirus vaccines. Lancet Infect Dis. 2019; 20(1):15-17. DOI: 10.1016/S1473-3099(19)30697-8. View

20.

Reinhardt B, Jaspert R, Niedrig M, Kostner C, Lage-Stehr J . Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998; 56(2):159-67. DOI: 10.1002/(sici)1096-9071(199810)56:2<159::aid-jmv10>3.0.co;2-b. View